Keros Therapeutics Inc (KROS)

Jan 17, 2025, 10:00 AM EST - 15 hours ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Keros Therapeutics, Inc. (KROS) And Encourages Investors to Reach Out

Jan 16, 2025, 2:30 PM EST - 1 day ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Keros Therapeutics, Inc. (KROS) And Encourages Stockholders to Reach Out

Jan 15, 2025, 6:41 AM EST - 2 days ago

Keros halts hypertension treatment trial on safety issues

Jan 15, 2025, 6:30 AM EST - 2 days ago

Keros Therapeutics Announces Additional Update on the Phase 2 TROPOS Trial

Dec 27, 2024, 10:00 AM EST - 21 days ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Keros Therapeutics, Inc. (KROS) And Encourages Shareholders to Reach Out

Dec 26, 2024, 10:00 AM EST - 22 days ago

Keros Therapeutics, Inc. (KROS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Dec 26, 2024, 10:00 AM EST - 22 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Shareholders to Learn More About the Investigation

Dec 24, 2024, 10:00 AM EST - 24 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages Keros Therapeutics, Inc. (KROS) Shareholders to Inquire about Securities Investigation

Dec 23, 2024, 10:00 AM EST - 25 days ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Keros Therapeutics, Inc. (KROS) And Encourages Investors to Connect

Dec 22, 2024, 10:00 AM EST - 26 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages Keros Therapeutics, Inc. (KROS) Stockholders to Inquire about Securities Investigation

Dec 20, 2024, 10:00 AM EST - 4 weeks ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Investors to Learn More About the Investigation

Dec 19, 2024, 10:00 AM EST - 4 weeks ago

Keros Therapeutics, Inc. (KROS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Dec 18, 2024, 7:10 AM EST - 4 weeks ago

Keros Therapeutics: Trading At Essentially Cash Value, Target Of $23 Per Share

Dec 17, 2024, 10:00 AM EST - 4 weeks ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Keros Therapeutics, Inc. (KROS) And Encourages Stockholders to Connect

Dec 16, 2024, 10:00 AM EST - 4 weeks ago

Keros Therapeutics, Inc. (KROS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Dec 15, 2024, 10:00 AM EST - 4 weeks ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Stockholders to Learn More About the Investigation

Dec 13, 2024, 10:00 AM EST - 5 weeks ago

Bronstein, Gewirtz & Grossman, LLC Encourages Keros Therapeutics, Inc. (KROS) Investors to Inquire about Securities Investigation

Dec 12, 2024, 9:29 AM EST - 5 weeks ago

Keros Therapeutics Loses 75% Value In A Single Session - Here's Why

Dec 12, 2024, 8:54 AM EST - 5 weeks ago

Adobe, Keros Therapeutics, Lovesac And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

ADBE LOVE

Dec 12, 2024, 6:37 AM EST - 5 weeks ago

Keros Therapeutics halts dosing of blood pressure treatment after safety review

Dec 12, 2024, 6:00 AM EST - 5 weeks ago

Keros Therapeutics Announces Update on the Phase 2 TROPOS Trial

Dec 9, 2024, 7:30 PM EST - 5 weeks ago

Keros Therapeutics Presents Clinical Data from its Elritercept Program at the 66th American Society of Hematology Annual Meeting and Exposition

Dec 3, 2024, 12:37 PM EST - 6 weeks ago

Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst

TAK

Dec 3, 2024, 7:00 AM EST - 6 weeks ago

Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics

TAK

Nov 6, 2024, 4:01 PM EST - 2 months ago

Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results

Nov 6, 2024, 8:00 AM EST - 2 months ago

Keros Therapeutics to Present at the Guggenheim Healthcare Innovation Conference

Aug 28, 2024, 8:00 AM EDT - 5 months ago

Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

Aug 7, 2024, 4:01 PM EDT - 5 months ago

Keros Therapeutics Reports Second Quarter 2024 Financial Results